Navigation Links
Roche and InterMune Initiate Phase 2b Clinical Trial of RG7227/ ITMN-191 in Patients With Chronic Hepatitis C
Date:8/19/2009

atients who have failed to respond to previous therapy.

Important Safety Information About PEGASYS

PEGASYS, alone or in combination with COPEGUS, is indicated for the treatment of adults with chronic hepatitis C virus infection who have compensated liver disease and have not been previously treated with interferon alpha. Patients in whom efficacy was demonstrated included patients with compensated liver disease and histological evidence of cirrhosis (Child-Pugh class A).

Alpha interferons, including PEGASYS, may cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders. Patients should be monitored closely with periodic clinical and laboratory evaluations. Therapy should be withdrawn in patients with persistently severe or worsening signs or symptoms of these conditions. In many, but not all cases, these disorders resolve after stopping PEGASYS therapy (see CONTRAINDICATIONS, WARNINGS, PRECAUTIONS and ADVERSE REACTIONS in complete product information).

Use with Ribavirin. Ribavirin, including COPEGUS, may cause birth defects and/or death of the fetus. Extreme care must be taken to avoid pregnancy in female patients and in female partners of male patients. Ribavirin causes hemolytic anemia. The anemia associated with ribavirin therapy may result in a worsening of cardiac disease. Ribavirin is genotoxic and mutagenic and should be considered a potential carcinogen (see CONTRAINDICATIONS, WARNINGS, PRECAUTIONS and ADVERSE REACTIONS in complete product information).

PEGASYS is contraindicated in patients with hypersensitivity to PEGASYS or any of its components, autoimmune hepatitis, and hepatic decompensation (Child-Pugh score greater than 6; class B and C) in cirrhotic CHC monoinfected patients before or during treatment. PEGASYS is also contraindicated in hepatic decompensation with Child-Pugh score greater than or eq
'/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Rochester Medical Reports Third Quarter Results
2. Roche Cardiac 200 Offers Rapid Cardiac Diagnostics for the Point of Care
3. Rochester Medical Announces Third Quarter 2009 Earnings Conference Call July 30, 2009
4. Enigma Diagnostics Announces Signing of Patent Licenses With Roche Molecular Systems, Inc.
5. Roche Diabetes Care Announces Unique Coaching Program for Diabetes Educators as Part of Long-Term Commitment to Fight the Disease
6. NJLRA Statement in Response to Roches Discontinuation of Accutane(R)
7. Orochem Technologies Acquires Oligonet, a Custom Oligo Synthesis Business
8. Purple Communications Dream Bigger Initiative Honors Rochester Physician and Deaf Community Trailblazer
9. Rochester Medical Corporation Set to Join Russell 3000 Index
10. Roche to Commence Phase III Trials with Innovative Treatment Designed to Lower Cardiovascular Risk in Diabetes Patients with Recent Heart Attack
11. Raptor Pharmaceuticals to Collaborate with Roche on Therapeutic Delivery Across Blood-Brain Barrier
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... 2014 (HealthDay News) -- Daily supplements of selenium or ... development of age-related cataracts among men, a new study ... or both could help prevent cataracts. To investigate this ... Harvard Medical School in Boston, and his colleagues examined ... vitamin E. The trial was initially designed to study ...
(Date:9/18/2014)... Lake City, UT (PRWEB) September 18, 2014 ... North America will be recognizing their shared fundraising impact ... on Thursday, Sept. 25. , The first-ever Dance Marathon ... more than $20 million projected to be raised by ... their community’s CMN Hospital. Donations generated through Dance Marathon ...
(Date:9/18/2014)... scientists have developed a new method to study Ebola ... The Wildlife Conservation Society (WCS)-led research, published today in ... the use of fecal samples from wild great apes ... the virus. This represents a new tool for performing ... way Ebola virus is studied and improve our understanding ...
(Date:9/18/2014)... Dangerous new pathogens such as the Ebola virus invoke ... such as the bubonic plague are still providing researchers ... infections. , In a study published online Sept. 18, ... Duke Medicine and Duke-NUS Graduate Medical School Singapore detail ... hitchhike on immune cells in the lymph nodes and ...
(Date:9/18/2014)... Technology Association of Georgia in collaboration ... TAG Social Savvy Awards this week at a special ... Center in Downtown Atlanta. The event celebrates Georgia’s best ... was honored with the 2014 TAG Social Savvy People’s ... innovators in 6 other award categories: , ...
Breaking Medicine News(10 mins):Health News:Vitamin E, Selenium Supplements Don't Seem to Prevent Cataracts 2Health News:250 Campuses Usher in School Year of Saving Kids’ Lives During First-Ever “Dance Marathon Day” on Sept. 25 2Health News:Research yields a game changer for improving understanding of Ebola and great apes 2Health News:Research yields a game changer for improving understanding of Ebola and great apes 3Health News:New insights on an ancient plague could improve treatments for infections 2Health News:Winners Honored at 2014 TAG Social Savvy Awards 2Health News:Winners Honored at 2014 TAG Social Savvy Awards 3
... A group of Northeast Ohio breast,cancer survivors continue to ... the disease by participating in the sport of Dragon ... canoeing, involves a team of 22,paddlers racing in 40-foot-long ... the team offers women living with breast cancer an,opportunity ...
... Increasing temperatures, carbon dioxide levels add to discomfort of ... Add increased suffering for people with ragweed allergies to ... new study suggests. , Recent research indicates that ... longer ragweed seasons and more concentrated pollen counts, says ...
... certain genotype more affected, study finds , , MONDAY, Aug. ... containing codeine may be unwittingly risking the health of ... indicates that a relatively rare genetic predisposition causes some ... than normal -- possibly harming the infant,s central nervous ...
... at menopause as well as a woman,s breastfeeding practices ... breast cancer. That was the conclusion of a new ... CANCER, a peer-reviewed journal of the American ... distinct and separate hormonal risk factors associated with different ...
... Bikes Belong and Humana, launches Freewheelin ... bike-sharing initiative ... Inaugural Ride, DENVER, Aug. 24 Bike-sharing officially,rolled into Denver ... date: Freewheelin. Leading 100 cyclists,through the streets of Denver, Mayor Hickenlooper ...
... Benefit Group, LLC announces iCan Insurance, LLC ("iCan Insurance", "iCan") ... Inc. , ... Boca Raton, FL ... iCan Insurance, LLC ("iCan Insurance", "iCan") is now offering major ...
Cached Medicine News:Health News:Dragon Dream Team Continues to Send Message of Hope a Year Later 2Health News:Climate Change Linked to Longer Pollen Seasons 2Health News:Taking Codeine While Breast-Feeding May Harm Infant 2Health News:Taking Codeine While Breast-Feeding May Harm Infant 3Health News:Breastfeeding, other factors may affect risk of breast cancer type 2Health News:Kicking Into High Gear: Nation's Largest Bike-Sharing Program Debuts at Democratic National Convention 2Health News:Kicking Into High Gear: Nation's Largest Bike-Sharing Program Debuts at Democratic National Convention 3Health News:Kicking Into High Gear: Nation's Largest Bike-Sharing Program Debuts at Democratic National Convention 4Health News:iCan Benefit Group, LLC Announces: Major Medical Division Now Offers Avalon Healthcare Products 2
(Date:9/18/2014)... Sept. 18, 2014   Regulus Therapeutics Inc ... company leading the discovery and development of innovative ... its ATHENA natural history of disease study in ... disease with no approved therapy. The ATHENA study ... renal function markers such as Glomerular Filtration Rate ...
(Date:9/18/2014)... and ROCKVILLE, Md. , ... SPPI ), a biotechnology company with fully integrated ... in hematology and oncology, and CASI Pharmaceuticals, Inc. (Nasdaq: ... the acquisition, development and commercialization of innovative therapeutics addressing ... market with a primary focus on China ...
(Date:9/18/2014)... Sept. 18, 2014  RXi Pharmaceuticals Corporation ... company focused on discovering, developing and commercializing ... using RNA-targeted technologies, today announced that the Company,s ... Geert Cauwenbergh , will present at the ... on Wednesday, September 24, 2014 at 11:20 ...
Breaking Medicine Technology:Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 2Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 3Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 4Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 5Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 6Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 2Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 3Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 4Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 5Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 6Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 7Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 8Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 9Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 10RXi Pharmaceuticals to Present at the 7th Annual BioPharm America Conference 2RXi Pharmaceuticals to Present at the 7th Annual BioPharm America Conference 3
... 2011 On Sunday, August 21, veterinary cardiologists are ... the Mobile Dog Heart Health Tour will stop with ... examinations at Peters Park Dog Run. (Photo: ... free heart health screenings, veterinarians will be available to ...
... Unilife Corporation ("Unilife" or the "Company") (NASDAQ: ... it has finalized a previously disclosed Equipment Financing ... $10 million in available funding. This agreement will ... finance the automated assembly line now manufacturing the ...
Cached Medicine Technology:Free Dog Heart Health Screenings Available August 21 in Boston 2Unilife Signs $10 Million Equipment Financing Agreement 2Unilife Signs $10 Million Equipment Financing Agreement 3Unilife Signs $10 Million Equipment Financing Agreement 4
Battery-driven vacuum system operates with a touch of a button....
... The D.O.R.C. Harmony Special Peristaltic phacoemulsification ... latest technology including individual programmability and remote ... system features a front panel with color ... LCD display for ease of use and ...
... an advanced ophthalmic system that integrates ... allowing surgeons to independently select either ... procedures.,The key feature of this futuristic ... that measures in-line vacuum pressure, ensuring ...
The D.O.R.C. CryoStar is the smart cryosurgical system that combines optimal performance with state-of-the-art automation. simple for O.R. staff to operate and maintain throughout every procedure....
Medicine Products: